by admin | Dec 5, 2023 | press-releases
Home PRESS RELEASE CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to...
by admin | Nov 30, 2023 | press-releases
Home PRESS RELEASE Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer 💻 DESKTOP AUDIO PLAYER =============================== --> Listen...
by admin | Nov 14, 2023 | press-releases
Home PRESS RELEASE CG Oncology Announces Presentation of the First Phase 3 Monotherapy Data for Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC Patients at SUO 2023 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱...
by admin | Sep 5, 2023 | press-releases
Home PRESS RELEASE CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER...
by admin | Aug 2, 2023 | press-releases
Home PRESS RELEASE CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Support Continued Advancement of Clinical-Stage Bladder Cancer Pipeline 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE...
by admin | Jul 24, 2023 | press-releases
Home PRESS RELEASE CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with cretostimogene grenadenorepvec in BCG-Unresponsive High-Risk NMIBC 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱...